Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.44 |
| ▸ | SCD | O00767 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676021 | 0.94 | SCD (0.44) | USP30SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3672411 | 0.92 | SCD (0.46) | EGLN1SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3670540 | 0.90 | SCD (0.47) | USP30SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3669208 | 0.90 | SCD (0.48) | EGLN1SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3668860 | 0.89 | SCD (0.46) | USP30SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3667904 | 0.87 | SCD (0.46) | EGLN1SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3670304 | 0.85 | SCD (0.51) | USP30EGLN1SCDHPGDSMN1; SMN2 | |
| SCHEMBL3670505 | 0.84 | SCD (0.57) | SCDHPGDSMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL3668937 | 0.84 | SCD (0.46) | USP30SCDHPGDSMN1; SMN2ALDH1A1 | |
| SCHEMBL3675434 | 0.84 | SCD (0.62) | USP30SCDHPGDSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | claimed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | claimed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | claimed |
| EP-1763350-B1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2011-12-21 | — | — | EP | disclosed |
| EP-2266566-A2 | Nicotinamide derivatives and their use as therapeutic agents | Xenon Pharmaceuticals Inc. (CA) | 2010-12-29 | — | — | EP | disclosed |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2009-08-06 | — | — | US | disclosed |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | MYRIAD GENETICS, INCORPORATED (US) | 2007-04-19 | — | — | US | disclosed |
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119251-A1 | Nicotinamide derivatives and their use as therapeutic agents | NAMPT, NNT, NNMT | USP30 4862/4885EGLN1 2179/4885SCD 10/4885 |
| US-20070087363-A1 | Therapeutic methods, compounds and compositions | APP, BACE1, PSEN1 | USP30 1539/4885EGLN1 2901/4885SCD 1186/4885 |
| US-20090197894-A1 | NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | NAMPT, NNT, NNMT | USP30 4862/4885EGLN1 2179/4885SCD 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.